GM21921
Fibroblast from Skin, Unspecified
Description:
ENCEPHALOPATHY, NEONATAL SEVERE, DUE TO MECP2 MUTATIONS
METHYL-CPG-BINDING PROTEIN 2; MECP2
|
Repository
|
NIGMS Human Genetic Cell Repository
|
| Subcollection |
Heritable Diseases |
|
Biopsy Source
|
Unspecified
|
|
Cell Type
|
Fibroblast
|
|
Tissue Type
|
Skin
|
|
Transformant
|
Untransformed
|
|
Sample Source
|
Fibroblast from Skin, Unspecified
|
|
Race
|
More than one race
|
|
Relation to Proband
|
proband
|
|
Confirmation
|
Molecular characterization before cell line submission to CCR
|
|
Species
|
Homo sapiens
|
|
Common Name
|
Human
|
|
Remarks
|
|
| PDL at Freeze |
3.06 |
| Passage Frozen |
6 |
| |
| IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin confirmed by LINE assay |
| |
| Gene |
MECP2 |
| Chromosomal Location |
Xq28 |
| Allelic Variant 1 |
p.I126fsC11; ENCEPHALOPATHY, NEONATAL SEVERE |
| Identified Mutation |
378_384delTCCCCAG |
| Remarks |
Clinically affected; congenital encephalopathy; hypotonia; hypoventlation; seizures with abnormal EEG; apnea; gastroesophageal reflux with failure to thrive; tube fed; respiratory failure at 5 months of age; high narrow palate; myopathic hypotonic facies; died at 15.5 months from central respiratory failure due to pneumonia; skin biopsy used to make this culture was taken 2 days prior to death; donor subject was hemizygous for a microdeletion in exon 4 of the MECP2 gene (r.378_384delTCCCCAG) resulting in a frameshift that leads to a premature stop codon (p.I126fsX11) |
| Schüle B, Armstrong DD, Vogel H, Oviedo A, and Francke U.
, Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure.
Clin Genet74(2):116-126 2008 |
| PubMed ID: 18477000 |
| Passage Frozen |
6 |
| Split Ratio |
1:3 |
| Temperature |
37 C |
| Percent CO2 |
10% |
| Percent O2 |
AMBIENT |
| Medium |
Dulbecco Modified Eagles Medium (high glucose) with 2mM L-glutamine or equivalent |
| Serum |
10% fetal bovine serum Not inactivated |
| Substrate |
None specified |
| Supplement |
- |
|
|